Equities analysts expect that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) will report earnings of ($0.13) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Achillion Pharmaceuticals’ earnings. Achillion Pharmaceuticals posted earnings of ($0.15) per share during the same quarter last year, which would suggest a positive year over year growth rate of 13.3%. The business is scheduled to report its next earnings results on Wednesday, May 1st.

On average, analysts expect that Achillion Pharmaceuticals will report full year earnings of ($0.57) per share for the current year, with EPS estimates ranging from ($0.58) to ($0.55). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.74) per share, with EPS estimates ranging from ($0.84) to ($0.63). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Achillion Pharmaceuticals.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03.

A number of equities analysts recently commented on the company. BidaskClub raised Achillion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 14th. William Blair reissued an “outperform” rating on shares of Achillion Pharmaceuticals in a research note on Thursday, March 7th. Zacks Investment Research raised Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, February 14th. Finally, ValuEngine lowered Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, December 18th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. Achillion Pharmaceuticals has an average rating of “Buy” and a consensus target price of $4.50.

A number of institutional investors have recently made changes to their positions in ACHN. Northern Trust Corp boosted its stake in Achillion Pharmaceuticals by 1.9% during the second quarter. Northern Trust Corp now owns 1,604,822 shares of the biopharmaceutical company’s stock valued at $4,541,000 after buying an additional 30,669 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Achillion Pharmaceuticals by 7.1% during the third quarter. JPMorgan Chase & Co. now owns 1,039,438 shares of the biopharmaceutical company’s stock valued at $3,825,000 after buying an additional 69,270 shares during the last quarter. BlackRock Inc. boosted its stake in Achillion Pharmaceuticals by 0.5% during the third quarter. BlackRock Inc. now owns 11,925,359 shares of the biopharmaceutical company’s stock valued at $43,885,000 after buying an additional 61,683 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Achillion Pharmaceuticals by 4.2% during the third quarter. Dimensional Fund Advisors LP now owns 7,182,715 shares of the biopharmaceutical company’s stock valued at $26,433,000 after buying an additional 290,531 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in Achillion Pharmaceuticals by 20.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,757 shares of the biopharmaceutical company’s stock valued at $452,000 after purchasing an additional 20,450 shares during the period. 75.22% of the stock is owned by institutional investors.

Shares of Achillion Pharmaceuticals stock opened at $3.13 on Tuesday. Achillion Pharmaceuticals has a 12 month low of $1.29 and a 12 month high of $4.06. The company has a market cap of $414.76 million, a P/E ratio of -6.14 and a beta of 2.45.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

Read More: Understanding Specialty Certificates of Deposit

Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.